<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838238</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-BREAST-X in Elder</org_study_id>
    <nct_id>NCT02838238</nct_id>
  </id_info>
  <brief_title>X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer</brief_title>
  <official_title>A Randomized, Phase II Study Comparing Single X (Xeloda/Capetabine) With Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <brief_summary>
    <textblock>
      Our study is a prospective, randomized phase II clinical trial, to compare the efficacy and&#xD;
      safety profiles of single X versus placebo as adjuvant chemotherapy regimens for elder breast&#xD;
      cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event rate (CTCAE v. 3.0)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine 1250mg/m², bid, po, d1-14, every 3 weeks for 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, bid, po, d1-14, every 3 weeks for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>X</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 70 years old.&#xD;
&#xD;
          -  Performance status (Karnofsky index) &gt;= 80.&#xD;
&#xD;
          -  Histological diagnosis of invasive breast cancer (T3-T4,N0-1,M0). Tumor must bu&#xD;
             hormone receptor negative. Time window between surgery and study randomization must be&#xD;
             less than 60 days.&#xD;
&#xD;
          -  Positive axillary lymph nodes defined as at least 1 out of 10 nodes with presence of&#xD;
             disease. If sentinel node technique is used, sentinel node can be the only node&#xD;
             affected.&#xD;
&#xD;
          -  Status of hormone receptors, HER2 status, Ki-67 index and p53 in primary tumour. ER&#xD;
             and PR negative. And patients with positive HER-2 status should revceive the standard&#xD;
             anti-targeted therapy.&#xD;
&#xD;
          -  Written informed consent. Patients are able to comply with treatment and study&#xD;
             follow-up.&#xD;
&#xD;
          -  Patients must not present evidence of metastatic disease.&#xD;
&#xD;
          -  Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed,&#xD;
             normal cardiac function must be confirmed by left ventricular ejection fraction&#xD;
             (LVEF).&#xD;
&#xD;
          -  Laboratory results (within 14 days prior to randomization):&#xD;
&#xD;
        Hematology: neutrophils &gt;= 2.0x10^9/l; platelets &gt;= 100x10^9/l; hemoglobin &gt;= 10 mg/dl;&#xD;
        Hepatic function: total bilirubin &lt;= 1 upper normal limit (UNL); SGOT and SGPT &lt;= 2.5 UNL;&#xD;
        alkaline phosphatase &lt;= 2.5 UNL. If values of SGOT and SGPT &gt; 1.5 UNL are associated to&#xD;
        alkaline phosphatase &gt; 2.5 UNL, patient is not eligible; Renal function: creatinine &lt;= 175&#xD;
        mmol/l (2 mg/dl); creatinine clearance &gt;= 60 ml/min.&#xD;
&#xD;
        ·Complete stage workup during the 12 weeks prior to randomization (mammograms are allowed&#xD;
        within a 20 week window). All patients must have a bilateral mammogram, thorax x-ray,&#xD;
        abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or alkaline&#xD;
        phosphatase elevation, a bone scintigraphy is mandatory. This test is recommended for all&#xD;
        patients. Other tests: as clinically indicated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic therapy for breast cancer.Or prior therapy with capecitabine for any&#xD;
             malignancy.&#xD;
&#xD;
          -  Prior radiotherapy for breast cancer.&#xD;
&#xD;
          -  Bilateral invasive breast cancer.&#xD;
&#xD;
          -  Any T4 or N2-3 or M1 tumour.&#xD;
&#xD;
          -  Pre-existing grade &gt;= 2 motor or sensorial neurotoxicity (National Cancer Institute&#xD;
             Common Toxicity Criteria version 2.0 [NCI CTC v-2.0]).&#xD;
&#xD;
          -  Any other serious medical pathology, such as congestive heart failure; unstable&#xD;
             angina; history of myocardial infarction during the previous year; uncontrolled HA or&#xD;
             high risk arrhythmias.&#xD;
&#xD;
          -  History of neurological or psychiatric disorders, which could preclude the patients&#xD;
             from free informed consent.&#xD;
&#xD;
          -  Active uncontrolled infection.&#xD;
&#xD;
          -  Active peptic ulcer; unstable diabetes mellitus.&#xD;
&#xD;
          -  Previous or current history of neoplasms different from breast cancer, except for skin&#xD;
             carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and&#xD;
             without recurrence in the last 10 years; ductal in situ carcinoma in the same breast;&#xD;
             lobular in situ carcinoma.&#xD;
&#xD;
          -  Chronic treatment with corticosteroids.&#xD;
&#xD;
          -  Concomitant treatment with raloxifene, tamoxifen or other selective estrogen receptor&#xD;
             modulators (SERMs), either for osteoporosis treatment or for prevention. These&#xD;
             treatments must stop before randomisation.&#xD;
&#xD;
          -  Concomitant treatment with other investigational products; participation in other&#xD;
             clinical trials with a non-marketed drug in the 20 previous days before randomization.&#xD;
&#xD;
          -  Concomitant treatment with another therapy for cancer.&#xD;
&#xD;
          -  Males.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yan Lin, Doctor</last_name>
    <phone>+86-10-69152700</phone>
    <email>birds90@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. Breast Surgery, PUMCH</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Lin, Doctor</last_name>
      <phone>+86-10-69152701</phone>
      <email>birds90@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 17, 2016</study_first_submitted>
  <study_first_submitted_qc>July 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>July 17, 2016</last_update_submitted>
  <last_update_submitted_qc>July 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Qiang SUN</investigator_full_name>
    <investigator_title>Chief of Dept. Breast Surgery, Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

